Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Xoma Corporation (XOMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 56,318
  • Shares Outstanding, K 7,590
  • Annual Sales, $ 5,560 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 3.15
  • Price/Sales 9.86
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.85 +8.03%
on 07/06/17
7.70 -3.90%
on 07/20/17
+0.46 (+6.63%)
since 06/27/17
3-Month
5.86 +26.28%
on 05/10/17
7.70 -3.90%
on 07/20/17
+0.44 (+6.32%)
since 04/27/17
52-Week
3.96 +86.87%
on 02/10/17
14.00 -47.14%
on 09/12/16
-4.40 (-37.29%)
since 07/27/16

Most Recent Stories

More News
XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development

XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced it has earned a $10 million milestone payment, reflecting the clinical advancement...

XOMA : 7.39 (-0.40%)
XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference

XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the Company's new strategic initiatives...

XOMA : 7.39 (-0.40%)
XOMA Reports First Quarter 2017 Financial Results

Established new corporate strategy leveraging extensive portfolio of partnered programs

XOMA : 7.39 (-0.40%)
Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA

NEW YORK, NY / ACCESSWIRE / April 25, 2017 / Markets rallied Monday after Centrist candidate Emmanuel Macron, an advocate of the European Union, won the first round of the French presidential election....

XOMA : 7.39 (-0.40%)
ACHN : 4.18 (-0.48%)
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition

XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that it has achieved positive Phase 2 proof-of-concept results for X213 in physiological...

XOMA : 7.39 (-0.40%)
XOMA (XOMA) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in XOMA Corporation (XOMA).

XOMA : 7.39 (-0.40%)
XOMA Announces Four Presentations at the 2017 ENDO Meeting

XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that clinical data for its two hypoglycemia drug candidates, X358 and X129, and a third...

XOMA : 7.39 (-0.40%)
Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy

Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2-...

XOMA : 7.39 (-0.40%)
NVS : 84.96 (+0.13%)
XNCR : 24.14 (+0.29%)
GSK : 40.52 (-0.81%)
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017

XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market...

XOMA : 7.39 (-0.40%)
XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference

XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the company's new strategic initiatives...

XOMA : 7.39 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1' with potential...

See More

Support & Resistance

2nd Resistance Point 7.57
1st Resistance Point 7.50
Last Price 7.39
1st Support Level 7.29
2nd Support Level 7.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.